Pharmaceutical Danish CNS drug specialist Lundbeck took a significant hit from generic competition in the first quarter of 2014, when the company posted a 21.6% drop in revenues to 4.58 billion Danish kroner ($850.8 million). However, this still beat analysts’ expectations of 3.61 billion kroner, according to the Wall Street Journal’s Market Watch. 7 May 2014